Background Emergence of drug resistance demands novel antimalarial drugs with new
mechanisms of action. We aimed to identify effective and well tolerated doses of …

Background Chloroquine was used for malaria treatment until resistant Plasmodium
falciparum was identified. Because 4-aminoquinolines with modified side chains, such as …

Background Achieving adequate antimalarial drug exposure is essential for curing malaria.
Day 7 blood or plasma lumefantrine concentrations provide a simple measure of drug …

Background Combination treatments, preferably containing an artemisinin derivative, are
recommended to improve efficacy and prevent Plasmodium falciparum drug resistance. Our …

Abstract Background In Zambia, unacceptably high resistance to commonly used
antimalarial drugs prompted the choice of artemether-lumefantrine (AL) as first line treatment …

Background Malaria remains a major public health problem, affecting mainly low-and middle-
income countries. The management of this parasitic disease is challenged by ever …

Background. Africa still bears the largest burden of malaria as the majority of infections in the
continent are caused by P. falciparum. Artemether‐lumefantrine (AL, Coartem®) is the most …

Introduction: WHO Treatment Guidelines recommend that artemisinin-based combination
therapies (ACTs) are used to treat uncomplicated Plasmodium falciparum malaria …

Background The six-dose regimen of artemether-lumefantrine is effective and is among
combination therapies prioritised to replace antimalarials that no longer work in Africa …

To demonstrate the superiority of the six-dose over the four-dose regimen of artemether–
lumefantrine (co-artemether, Coartem®) in patients> 12 years, data from 11 randomized …